ArticleAnnals of clinical microbiology and antimicrobials2023
Prevalence and factors associated with carbapenem-resistant Enterobacterales (CRE) infection among hematological malignancies patients with CRE intestinal colonization.
Article in Annals of clinical microbiology and antimicrobials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 18 citations in OpenAlex.
- Observational
- Prevalence and clinical outcomes of Carbapenemase-Producing Enterobacterales (CPE) colonization in patients with solid organ malignancies: a prospective study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- NDM-ProducingJournal of clinical medicine · 2026Article
- Epidemiology and clinical outcomes of carbapenamase-producing organism (CPO) colonization: a tertiary care center experience in Saudi Arabia.BMC infectious diseases · 2026Article
- Progression from Carbapenem-Resistant Enterobacterales Colonization to Bacteremia in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Cohort Study.Mediterranean journal of hematology and infectious diseases · 2026Article
- Carbapenem-resistant Enterobacterales bacteraemia at a tertiary hospital: A five-year review.Southern African journal of infectious diseases · 2026Article
- Characteristics of the resistome and the potential for bloodstream infections in patients with gut colonization byFrontiers in cellular and infection microbiology · 2026Article
- Microbiome dysbiosis and chemotherapy resistance in acute myeloid leukemia (AML).NPJ biofilms and microbiomes · 2025Review
- Intestinal colonization of carbapenem-resistant gram-negative bacteria in pediatric hematology patients: risk factors and molecular characteristics, a multicenter case-control study.BMC microbiology · 2025Article
- Incidence and risk factors of active carbapenem-resistant enterobacteriaceae surveillance in hematology patients: a propensity score matching study.Frontiers in microbiology · 2025Article
- A nosocomial outbreak of colistin and carbapenem-resistant hypervirulent Klebsiella pneumoniae in a large teaching hospital.Scientific reports · 2024Article
- Risk factors and molecular characterization of carbapenem resistant Escherichia coli recovered from a tertiary hospital in Fujian, China from 2021 to 2023.BMC microbiology · 2024Article
- Multidrug-Resistant Bacteria in Immunocompromised Patients.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria andAntibiotics (Basel, Switzerland) · 2024Review
- Risk factors of Carbapenem-resistant Enterobacterales intestinal colonization for subsequent infections in hematological patients: a retrospective case-control study.Frontiers in microbiology · 2024Article
- Carbapenem-Resistant Gram-Negative Bacteria Colonization in Immunocompromised and Critically Ill Pediatric Patients: Prevalence, Risk Factors, and Outcomes.Sage open pediatricsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundKnowledge about the prevalence, factors and mortality associated with subsequent carbapenem-resistant Enterobacterales (CRE) infection among hematological malignancies (HM) patients colonized with CRE is limited.
methodsHM patients were screened for rectal CRE. A retrospective case-control study of subsequent CRE infection among HM patients colonized with CRE was conducted between January 1st, 2020 and January 31st, 2022. Cases were defined as CRE colonized patients with subsequent infection and controls were those without infection. Bacterial identification was performed using MALDI Biotyper and antimicrobial susceptibility testing of strains was carried out using the VITEK 2 system or standard broth microdilution method. Logistic analysis was used for analyzing associated factors and Kaplan-Meier method was used for survival estimates.
resultsA total of 953 HM patients were screened for rectal CRE and 98 (10.3%, 98/953) patients were colonized with CRE. Among the 98 colonized patients, 18 (18.4%, 18/98) patients developed subsequent infection. Most of the colonizing CRE isolates were Klebsiella pneumoniae (50.0%, 27/54), followed by Escherichia coli (27.8%, 15/54) and Enterobacter cloacae (9.3%, 5/54). As for the subsequent infecting CRE isolates, the dominated species was K. pneumoniae (55.6%, 10/18), followed by E. coli (33.3%, 6/18) and others (11.2%, 2/18). Receiving proton pump inhibitors and admission to ICU (P < 0.05) were the associated factors. Patients with subsequent CRE infection had significant higher mortality (33.3% vs 2.8%, P = 0.001) and shock was an associated factor (P = 0.008).
conclusionsKlebsiella pneumoniae was the dominate colonizing species and subsequent infecting species among HM patients with CRE colonization. Receiving proton pump inhibitors and admission to ICU increased the risk of subsequent CRE infection among CRE colonized HM patients. Implementing strict infection control measures targeting those high- risk patients may prevent subsequent CRE infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.